

## Grifols obtains approval from the European Medicines Agency for the entire value chain of Grifols Egypt

- *The institution's certification endorses the entire plasma value chain under the highest European standards*
- *This milestone consolidates a project backed by Grifols' seal of quality, safety and national self-sufficiency*
- *The model guarantees Egypt's supply with national plasma and opens the door to exporting it to other markets, including Europe*

**Barcelona, Spain, December 16, 2025** - Grifols, S.A. (MCE: GRF, NASDAQ: GRFS), a global leader in plasma-derived medicines and innovative healthcare solutions, has received certification from the European Medicines Agency (EMA) for the entire value chain of Grifols Egypt for Plasma Derivatives (GEPD) in Egypt. The authority responsible for the scientific evaluation, supervision and safety control of medicines in the European Union has endorsed that the entire Grifols Egypt plasma platform operates under the most demanding European standards of quality, safety and regulatory control.

This recognition positions Egypt as the first country in Africa and the Middle East to operate a fully integrated plasma collection and processing system that meets the strictest international standards throughout the entire cycle, from donor medical assessment, donation, testing and plasma processing to the supply of plasma-derived medicines to patients. This milestone enables the country, once national needs are met, to move forward with exporting surplus Egyptian plasma-derived medicines to other markets, particularly Europe.

Tomás Dagá, Vice President of Grifols Egypt and member of Grifols Board's Strategy Committee, said: "This certification confirms the quality and rigor of the work carried out by the teams involved over these five years to create Africa's first integrated plasma platform and align it with the most demanding international quality and safety standards. EMA's certification of Grifols Egypt ensures that the medicines obtained from this plasma may be supplied to other markets once Egypt's national requirements are met."

Dagá added: "With Grifols' seal of quality and safety and the certification of European authorities, Egypt is in a privileged position to become a key player in the international pharmaceutical industry, supported by an industrial project, the creation of skilled local employment, the development of local expertise and the ability to meet national healthcare needs. Grifols has a long-term commitment to Egypt and its public health and will continue working to ensure the stable supply of essential medicines, which is already a reality."

This approval follows Egypt's announcement that it had achieved 100% self-sufficiency in plasma-derived medicinal products thanks to Grifols, making it the sixth country in the world capable of supplying itself with medicines derived from national plasma, after the U.S., Germany, Austria, the Czech Republic and Hungary. This milestone will allow Egypt to position itself as a regional hub to supply surplus medicines to the Africa and Middle East region.

## **Egypt, a new healthcare hub for Europe with Grifols' seal**

Plasma-derived medicines are identified by the EMA as critical and essential medicines for treating severe, chronic and potentially life-threatening diseases for which no alternative treatments exist. These medicines improve both life expectancy and quality of life for people suffering from deficiencies in certain plasma proteins, and the ability to rely on additional, robust supply chains that meet the highest standards of quality and safety for donors and patients directly contributes to strengthening the continent's healthcare resilience.

Currently, 65% of the plasma used worldwide to manufacture plasma-derived medicines comes from the United States, from which Europe imports nearly 40% of the plasma it needs. This heavy external dependence exposes the system to vulnerability in the event of supply disruptions. EMA's certification of the Grifols Egypt project is of strategic significance: it positions Egypt, in partnership with Grifols, as a new healthcare hub capable of helping reinforce Europe's plasma-supply security.

This regulatory recognition aligns with the priorities of the new SoHo Regulation, which highlights the need to ensure a stable supply of plasma-derived medicines. In this regard, Grifols Egypt, under the "Grifols Seal," strengthens Grifols' existing capacity to support the European market's supply.

This certification is further underpinned by the successful completion of PPTA (Plasma Protein Therapeutics Association) inspections to ensure compliance with the highest safety and quality standards in the new facilities.

## **An unprecedented economic, social and healthcare impact**

With a joint investment of €280 million and a focus on education, knowledge transfer and skilled employment, the public-private partnership between Grifols and the Government of Egypt has enabled, in record time, the creation of Africa's first fully integrated plasma ecosystem and one of the most advanced in the world.

With 16 donation centers, plus four more expected in 2026, a state-of-the-art testing laboratory and an integrated logistics center ensuring traceability across the entire chain, the country has achieved clinical self-sufficiency in immunoglobulins, albumin and coagulation factors for the first time. The future processing plant, whose first phase will become operational in 2026, will complete the entire value chain within Egypt, reducing dependence on the international market and expanding therapeutic options for patients with chronic and rare diseases.

This healthcare progress translates into tangible outcomes: more than one million vials produced with Egyptian plasma have been delivered to public hospitals and health centers, and more than 100,000 free medical check-ups have been provided to donors. The accumulated clinical impact of plasma therapies exceeds €80 million in health benefits thanks to increased diagnosis, treatment and preventive capacity. Egypt has also strengthened its healthcare infrastructure through collaborations with the World Federation of Hemophilia (WFH) and IPOPI (International Patient Organization for Primary Immunodeficiencies), enabling training programs and donations of coagulation factors that enhance system resilience and autonomy.

From an economic and social perspective, the project has become a national driver. In 2025, Grifols, through Grifols Egypt, will contribute €55 million to Egypt's GDP and is expected to reach more than €272 million annually by 2030. Over the 2026–2029 growth plan, direct investments of nearly €209 million will generate a total impact exceeding



€700 million, driven by the project's direct, indirect and induced effects. This development is also reflected in employment: 1,200 highly skilled direct jobs have been created to date, together with more than 14,000 indirect and induced jobs; and between 2026 and 2029 the creation of a total of 186,000 new jobs is expected.

Local capacity building is another strategic pillar of the project. The Grifols Academy for Plasmapheresis, the first African institution dedicated to this technical training, has delivered more than 170,000 hours of instruction under international standards and has prepared Egyptian personnel to operate the system with full autonomy. This is complemented by collaboration with national universities to train specialized profiles and consolidate an independent professional ecosystem.

### **About Grifols Egypt for Plasma Derivatives (GEPD)**

Grifols Egypt for Plasma Derivatives is a joint-venture company between Egypt's National Service Projects Organization and Grifols. Under the terms of the joint venture, NSPO owns 51% and Grifols the balance. The strategic partnership's combined expertise, technology and resources seek to strengthen Egypt's healthcare system through achieving self-reliance in plasma-derived medicines while reinforcing Grifols' international expansion in the Middle East and Africa.

### **About Grifols**

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols nonvoting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)

### **MEDIA CONTACTS:**

**Grifols Press Office**

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

### **INVESTORS:**

**Investor Relations and Sustainability**

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)



[sostenibilidad@grifols.com](mailto:sostenibilidad@grifols.com) - [sustainability@grifols.com](mailto:sustainability@grifols.com)

Tel. +34 93 571 02 21

#### **LEGAL DISCLAIMER**

*The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.*